Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma
NCT ID: NCT00065351
Last Updated: 2019-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
222 participants
INTERVENTIONAL
2003-07-01
2007-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Treatment Phase: Subjects who qualify for enrollment into the study will receive single-agent CC-5013 in 28-day cycles. Study visits will occur every 4 weeks and hematologic and myeloma paraprotein laboratory assessments will occur every 2 weeks for the first 6 cycles and every 4 weeks thereafter.
Follow-Up Phase: All subjects who discontinue the treatment phase for any reason will continue to be followed for survival and post-treatment phase anti-myeloma treatment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
NCT00153933
Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT04975399
An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
NCT03601078
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
NCT03275103
CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma
NCT00044018
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
CC-5013 - oral - 30mg daily on days 1-21 every 28 days
CC-5013
CC-5013 - oral - 30mg daily on days 1-21 every 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CC-5013
CC-5013 - oral - 30mg daily on days 1-21 every 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age greater than or equal to 18 years at the time of signing the informed consent form.
* Must have a diagnosis of multiple myeloma and have relapsed and refractory disease. Such subjects have relapsed after having had at least a partial myeloma paraprotein response (greater or equal to 50% reduction of myeloma paraprotein) to prior therapy and then continued to develop disease progression despite salvage anti-myeloma therapy. Subjects must have documented evidence of disease progression during therapy with the last prior anti-myeloma treatment regimen (must have received at least 2 cycles) prior to study enrollment.Subjects may have been previously treated with thalidomide and/or radiation therapy.
* Measurable levels of myeloma paraprotein in serum (greater or equal to 0.5 g/dL) or urine (greater or equal to 0.2 g excreted in a 24-hour collection sample).
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2 (see Appendix II).
* Able to adhere to the study visit schedule and other protocol requirements
* Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug.
Exclusion Criteria
* WCBP must agree to have pregnancy tests every 4 weeks while on study drug (every 14 days for women with irregular cycles) and 4 weeks after the last dose of study drug.
* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
* Pregnant or lactating females.
* Any of the following laboratory abnormalities:
A) Absolute neutrophil count (ANC) \<1,000 cells/mm\^3 (1.0 x 10\^9/L) B) Platelet count \<75,000/mm\^3 (75 x 10\^9/L) C) Serum creatinine \>2.5 mg/dL (221 umol/L) D) Serum SGOT/AST or SGPT/ALT \>3.0 x upper limit of normal (ULN) E) Serum total bilirubin \>2.0 mg/dL (34 umol/L)
* Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
* Prior history of malignancies other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for greater than or equal to 3 years.
* Prior greater than or equal to grade 3 allergic reaction/hypersensitivity to thalidomide.
* Prior greater than or equal to grade 3 rash or any desquamating (blistering) rash while taking thalidomide.
* Prior use of CC-5013.
* Use of any standard/experimental anti-myeloma drug therapy within 28 days of the initiation of study drug therapy or use of any experimental non-drug therapy within 56 days of the initiation of study drug therapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Celgene
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Knight, MD
Role: STUDY_DIRECTOR
Celgene
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Palo Verde Hematology Oncology
Glendale, Arizona, United States
Mayo Clinic
Scottsdale, Arizona, United States
Alta Bates Comprehensive Cancer Center
Berkeley, California, United States
Providence St. Joseph Medical Center/Cancer Center
Burbank, California, United States
Wilshire Oncology Medical Group, Inc.
La Verne, California, United States
Institute for Myeloma and Bone
Los Angeles, California, United States
Cancer Care Associates
Redondo Beach, California, United States
Mayo Clinic
Jacksonville, Florida, United States
Northwest Georgia Oncology Centers
Marietta, Georgia, United States
Atlanta Cancer Care-Roswell
Roswell, Georgia, United States
Northwestern University Med Ctr
Chicago, Illinois, United States
Midwest Cancer Research Group
Skokie, Illinois, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
University of Massachusetts
Worcester, Massachusetts, United States
Mayo Clinic
Rochester, Minnesota, United States
Nevada Cancer Center
Las Vegas, Nevada, United States
SUNY Health Science Center at Brooklyn
Brooklyn, New York, United States
St. Vincent's Comprehensive Cancer Center
New York, New York, United States
Carolina Hematology-Oncology Associates
Charlotte, North Carolina, United States
Cleveland Clinic Myeloma Program Hematology & Medical Oncology /R35
Cleveland, Ohio, United States
Western Pennsylvania Cancer Institute
Pittsburgh, Pennsylvania, United States
Swedish Cancer Institute
Seattle, Washington, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009 Jul 23;114(4):772-8. doi: 10.1182/blood-2008-12-196238. Epub 2009 May 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CC-5013-MM-014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.